Skip to Main Content
David Miller, M.D.

David Miller, M.D.

Titles and Appointments

Professor

Endowed Title
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science; Dallas Foundation Chair in Gynecologic Oncology
School
Medical School
Department
Obstetrics and Gynecology

You have reached the Academic Profile.

For more information on the doctor and patient care, please visit the clinical profile.

  • Biography

    David Scott Miller, Professor in the Department of Obstetrics and Gynecology, is Medical Director for the Division of Gynecologic Oncology's practice at the NCI-designated Harold C. Simmons Cancer Center.

    Dr. Miller also serves as principal investigator for the National Cancer Institute’s Gynecologic Oncology Group program at UT Southwestern and participates in the cancer treatment protocols developed by that organization.

    A graduate of the University of Oklahoma College of Medicine, Dr. Miller completed his residency in obstetrics and gynecology at the Hospital of the Medical College of Pennsylvania. After residency, he pursued a reproductive endocrinology fellowship at the University of California-San Diego and a gynecologic oncology fellowship at Stanford University Medical Center. Before joining the faculty at UT Southwestern in 1991, he practiced gynecologic oncology at Northwestern University Medical School in Chicago.

    Widely-known as an authority on cancers of the female reproductive system, Dr. Miller is board certified in both obstetrics and gynecology and gynecologic oncology. He serves as an examiner for the American Board of Obstetrics and Gynecology, where he participates in the oral examination of physicians seeking certification as specialists in gynecologic oncology.  He is a member of the Society of Gynecologic Oncologists, American Society of Clinical Oncology, American Congress of Obstetricians and Gynecologists, and the American College of Surgeons.

    Dr. Miller believes the gynecologic oncology team’s strength comes from its collaborative approach to health care and commitment to search for the best treatment options for women with cancer of the reproductive system. This approach goes beyond treatment of the cancer itself to include the patient’s nutrition and pain management as well as psychological and social adjustments.

  • Education
    Medical School
    University of Oklahoma College of Medicine (1977)
    Internship
    Medical College of Pennsylvania (1978), Obstetrics & Gynecology
    Residency
    Medical College of Pennsylvania (1981), Obstetrics & Gynecology
    Fellowship
    University of California at San Diego (1982), Gynecologic Oncology
    Fellowship
    Stanford University Hospital (1985), Gynecologic Oncology
  • Research Interest
    • Antineoplastic drug development
    • Clinical trials
    • Gynecologic Oncology
    • Reconstructive pelvic surgery
  • Publications
    Surgical staging identifies occult metastases in over 50% of uterine-confined carcinosarcoma
    Vintzileos W, Beer H, Miller D, Lea J Gynecologic Oncology Reports 2025 Apr 58
    Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma
    Matei DE, Enserro DM, Randall ME, Mutch D, Small W, Disilvestro PA, Spirtos NM, O'Malley DM, Cantuaria GH, Michelin D, Waggoner S, Shahin M, Guntupalli S, Lara O, Ueland FR, Warshal D, Bonebrake A, Tewari KS, Tan A, Powell MA, Walker JL, Santin AD, Kim JH, Miller DS Journal of Clinical Oncology 2025 Mar 43 1055-1060
    Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258
    Clements A, Enserro D, Strickland KC, Previs R, Matei D, Mutch D, Powell M, Klopp A, Miller DS, Small W, DiSilvestro P, Spirtos N, Cosgrove C, Sfakianos G, Liu JR, Vargas R, Shahin M, Corr B, Dessources K, Ueland F, Warshal D, Gillen J, Secord AA Gynecologic oncology 2025 Feb 193 119-129
    Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14
    Brown J, Miller A, Holman LL, Backes F, Nagel C, Bender D, Miller DS, Powell MA, Westin SN, Bonebrake A, Muller CY, Secord AA, Crane E, Schorge J, Tew WP, Sood AK, Bookman MA, Aghajanian C, Gershenson DM Gynecologic oncology 2024 Nov 190 283-290
    NCCN GUIDELINES® INSIGHTS CE Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
    Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, Martin L, Matei D, Miller DS, Robertson S, Barroilhet L, Uppal S, Hendrickson AW, Gershenson DM, Gray HJ, Hakam A, Jain A, Konecny GE, Moroney J, Ratner E, Schorge J, Thaker PH, Werner TL, Zsiros E, Behbakht K, Chen LM, DeRosa M, Eisenhauer EL, Leiserowitz G, Litkouhi B, McHale M, Percac-Lima S, Rodabaugh K, Vargas R, Jones F, Kovach E, Hang L, Ramakrishnan S, Alvarez RD, Armstrong DK JNCCN Journal of the National Comprehensive Cancer Network 2024 Oct 22 512-519
    Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer
    Walker CA, Edwards C, McIntire D, Makepeace L, Holloway SB, Kakadiaris E, Spirtos AN, Miller DS, Lea JS Gynecologic oncology 2024 Sep 188 22-26
    Radiation Therapy with or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results from an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial
    Klopp AH, Enserro D, Powell M, Randall M, Schink JC, Mannel RS, Holman L, Bender D, Kushnir CL, Backes F, Zweizig SL, Waggoner S, Bradley KA, Lawrence LD, Hanjani P, Darus CJ, Small W, Cardenes HR, Feddock JM, Miller DS Journal of Clinical Oncology 2024 Jul 42 2425-2435
    Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279
    Horowitz NS, Deng W, Peterson I, Mannel RS, Thompson S, Lokich E, Myers T, Hanjani P, O'Malley DM, Chung KY, Miller DS, Ueland FR, Dizon DS, Miller A, Mayadev JS, Leath CA, Monk BJ Journal of Clinical Oncology 2024 Jun 42 1914-1921
    Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
    Makker V, Perez-Fidalgo JA, Valabrega G, Hamilton E, Van Gorp T, Sehouli J, Regináčová K, Richardson DL, Perri T, Oza AM, Miller DS, Alía EM, De Giorgi U, Henry S, Spitz DL, Wimberger P, Bednaříková M, Chon HS, Martínez-Garcia J, Pisano C, Berek JS, Romero I, Scambia G, Fariñas-Madrid L, Buscema J, Schochter F, Li K, Kalyanapu P, Walker CJ, Vergote I Gynecologic oncology 2024 Jun 185 202-211
    Social determinants of health in uterine carcinosarcoma
    Aroche Gutierrez LL, McIntire DD, Lea J, LoCoco S, Miller DS Gynecologic oncology 2024 May 184 117-122
  • Honors & Awards
    • Top Doctor - Gynecologic Oncology / Gynecology
      U.S. News and World Report (2013-2021)
    • D Best Doctor - Gynecological Oncology
      D Magazine (2010-2023)
    • Super Doctors in Texas - Gynecologic Oncology / Obstetrics & Gynecology
      Texas Monthly - Super Doctors (2004-2025)
    • National Faculty Award
      Council on Resident Education in Obstetrics & Gynecology (2000)
    • Senior Residents Award for Outstanding Faculty Teacher
      Department of Obstetrics & Gynecology, University of Texas Southwestern Medical Center at Dallas (2000)
    • First Prize Scientific Paper Award
      American College of Obstetricians & Gynecologists, 39th Annual Meeting (1991)
  • Professional Associations/Affiliations
    • American College of Obstetricians & Gynecologists
    • American College of Surgeons
    • American Society of Clinical Oncology
    • Gynecologic Oncology Group
    • Society of Gynecologic Oncology